In April 2022, Genmab and AbbVie announced the topline results from the Phase II expansion part of the EPCORE NHL-1 trial. Genmab recently announced that the company will submit a biologics license application (BLA) for epcoritamab with the U. In June 2022, primary results were presented in.
💼 Business Developments:
✅ Partnership/Collaboration
❌ Acquisition Activity: Not reported
❌ Licensing Agreement: Not reported
✅ Regulatory Milestone
❌ Leadership Updates: Not reported
📞 Contact Information:
Media Contact: :Marisol Peron, Senior Vice President, Communications and Corporate AffairsT: +1
🌍 Genmab (GMAB) - Form 6-K Filing
Filing Date: 2022-07-18
Accepted: 2022-07-18 11:08:42
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: